Syneos Survey Clarifies Payer Understanding for Rare Disease RWE

November 21, 2019

Pharmaceutical Executive

Syneos Health announced the release of its survey “Real World Value: Advancing Payer Understanding of RWE in Rare Disease.” The survey talks about the perception gap that payers have surrounding RWE benefits for rare disease therapies. It also provides feedback from more than 300 payers in the U.S. and Europe, exploring the acceptability of RWE on payer decisions for rare therapies and perspectives on how their stance is likely to evolve over time.

Syneos Health announced the release of its survey “Real World Value: Advancing Payer Understanding of RWE in Rare Disease.” The survey talks about the perception gap that payers have surrounding RWE benefits for rare disease therapies. It also provides feedback from more than 300 payers in the U.S. and Europe, exploring the acceptability of RWE on payer decisions for rare therapies and perspectives on how their stance is likely to evolve over time.

Some of the survey findings include:

  • The need for standard RWE lexicon

  • Varying perceptions of RWE benefits among payers worldwide

  • Reputable sources for decision making (sources include peer-reviewed literature and health economics and outcomes research)

Read or download the full report here.